Publication Name	World Journal of Meta-Analysis
Manuscript ID	62113
Country	China

Received	2020-12-29 05:48
Peer-Review Started	2020-12-29 09:36
To Make the First Decision
Return for Revision	2021-10-11 13:02
Revised	2021-10-14 14:11
Second Decision	2021-12-24 04:50
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2021-12-24 08:22
Articles in Press	2021-12-24 08:22
Publication Fee Transferred
Edit the Manuscript by Language Editor	2021-12-14 09:57
Typeset the Manuscript	2021-12-26 15:43
Publish the Manuscript Online	2021-12-28 09:18

ISSN	2308-3840 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Opinion Review
Article Title	Is dose modification or discontinuation of nilotinib necessary in nilotinib-induced hyperbilirubinemia?
Manuscript Source	Invited Manuscript
All Author List	You-Wen Tan
ORCID	Author(s) ORCID Number You-Wen Tan http://orcid.org/0000-0002-5464-1407
Funding Agency and Grant Number	Funding Agency Grant Number the social development project of Jiangsu Province BE2020775 Medical Project of Health Department Jiangsu Province H201802
Corresponding Author	You-Wen Tan, MD, Chief Doctor, Professor, Department of Hepatology, The Third Hospital of Zhenjiang Affiliated Jiangsu University, Danjiamen 300,runzhouqu,zhenjiang, Zhenjiang 212003, Jiangsu Province, China. tyw915@sina.com
Key Words	Tyrosine kinase inhibitors; Nilotinib; Chronic myelogenous leukemia; Hyperbilirubinemia; Drug induced liver injure; Liver injury
Core Tip	Hepatotoxicity due to nilotinib is a commonly reported side effect; however, abnormal liver function test (LFT) results have been reported in asymptomatic cases. Nilotinib-induced hyperbilirubinemia manifests usually as indirect bilirubinemia without observation of elevated alanine aminotransferase or aspartate aminotransferase levels. The underlying mechanism may be related to the inhibition of uridine diphosphate glucuronosyltransferase activity. Therefore, in the absence of elevated levels of liver enzymes or presence of abnormal LFT findings, physicians should consider maintaining nilotinib dose intensity without modifications.
Publish Date	2021-12-28 09:18
Citation	Tan YW. Is dose modification or discontinuation of nilotinib necessary in nilotinib-induced hyperbilirubinemia? World J Meta-Anal 2021; 9(6): 488-495
URL	https://www.wjgnet.com/2308-3840/full/v9/i6/488.htm
DOI	https://dx.doi.org/10.13105/wjma.v9.i6.488

Full Article (PDF)	WJMA-9-488.pdf
Full Article (Word)	WJMA-9-488.docx
Manuscript File	62113_Auto_Edited-ML_WangTQ.docx
Answering Reviewers	62113-Answering reviewers.pdf
Audio Core Tip	62113-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	62113-Conflict-of-interest statement.pdf
Copyright License Agreement	62113-Copyright license agreement.pdf
Approved Grant Application Form(s) or Funding Agency Copy of any Approval Document(s)	62113-Grant application form(s).pdf
Non-Native Speakers of English Editing Certificate	62113-Language certificate.pdf
Peer-review Report	62113-Peer-review(s).pdf
Scientific Misconduct Check	62113-Bing-Liu M-2.png
Scientific Editor Work List	62113-Scientific editor work list.pdf